CD40 and myeloid sarcoma: Lastly, attempts have been made to counteract dysregulated CD40 signaling in MS: defective regulation of CD40-stimulation on brain-derived neurotrophic factor levels in untreated relapse-remitting MS was found to be reversible with IFN-beta1a therapy [47].